ATRX - Adhera Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0450
+0.0110 (+32.35%)
At close: 9:47AM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0340
Open0.0340
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0335 - 0.0450
52 Week Range0.0200 - 0.2200
Volume3,100
Avg. Volume24,609
Market Cap489,127
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-1.2430
Earnings DateJun 29, 2020 - Jun 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Adhera Therapeutics Announces Third Quarter 2019 Financial Results and Operational Highlights

    RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / November 14, 2019 / Adhera Therapeutics, Inc. (ATRX), an emerging specialty pharmaceutical company that commercializes and delivers effective, patient-centric treatment in chronic care, to improve and simplify the quality of care for patients suffering from chronic diseases, reported financial and operating results for the third quarter of 2019 today. During the third quarter the Company achieved three important milestones in progressing its ‘invest to grow' strategy and removing barriers to performance, by scaling up 1) its marketing capabilities, 2) its distribution capabilities and 3) its product portfolio. Marketing - The Company entered into a strategic partnership with Indegene Inc. to deploy Indegene's proprietary co-commercialization model to expand commercialization for the Company's primary product, Prestalia®, across the United States.

  • GlobeNewswire

    Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock

    Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced offer to exchange all of the outstanding shares of the Series E Convertible Preferred Stock and Series F Convertible Preferred Stock of the Company. As per the terms of the offer, the Company offered, in exchange for each share of preferred stock tendered, such number of shares of the common stock of the Company as is equal to the quotient obtained by dividing (A) the “stated value” of such tendered share of preferred stock by (B) $0.50 (subject to an adjustment mechanism described in the Schedule TO).

  • ACCESSWIRE

    Adhera Therapeutics and Indegene Announce Next Gen Commercialization Partnership

    RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 10, 2019 / Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into a partnership with Indegene Inc. to deploy the proprietary Indegene co-commercialization model to expand commercialization for its drug, PRESTALIA®, across the United States. PRESTALIA® (https://PRESTALIA-us.net/package-insert) combines two key hypertensive agents, perindopril arginine and amlodipine besylate, and is indicated for the treatment of hypertension.

  • ACCESSWIRE

    Adhera and Allegis Pharma Announce Co-Promotion Agreement

    RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 6, 2019 / Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into an agreement with Allegis Pharmaceuticals, LLC to co-promote Allegis’ Nitrolingual® Pumpspray, a nitroglycerin lingual spray, indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin is listed as one of the top 300 most prescribed drugs with approximately 3.4 million annual prescriptions in 2016 (https://clincalc.com/DrugStats/Top300Drugs.aspx).

  • GlobeNewswire

    Adhera Therapeutics Announces Termination of Tender Offer for Warrants

    Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced offer to exchange all of the warrants to purchase shares of the common stock of the Company that the Company issued in connection with its private placements of Series E Convertible Preferred Stock and Series F Convertible Preferred Stock during 2018. As per the terms of the offer, the Company offered two shares of its common stock in exchange for each warrant tendered.